Edward Andrew Ashton1, Renuka Iyer2
1R&D, VirtualScopics, Inc.,
Rochester, NY, United States; 2Oncology, Roswell Park Cancer
Center, Buffalo, NY, United States
This
study assessed ADC measurement as a marker for response in oncology
trials. An evaluation of variability
in ADC in liver tissue was carried out using twelve volunteers. Results showed that ADC can be measured in
liver with CoV < 10%. Subsequently, ADC changes from baseline were
measured in HCC patients after therapy with an anti-angiogenic agent and/or
chemoembolization. Ktrans measurements
were also obtained for these patients using DCE- MRI, which is known to be a
good marker for changes associated with these therapies. Results show that changes in Ktrans are
highly correlated with changes ADC.